Explore (New York, N.Y.) · 2026
Improvement in postural imbalance with intake of resveratrol (polyphenolic phytoalexin) in patients of knee osteoarthritis.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karim Asima, Khan Haroon Ahmed, Ahmad Firdos, Qaisar Rizwan
Аннотация
PURPOSE: Knee osteoarthritis (OA) and postural imbalance are interlinked, increasing fall risk in older adults. The effective therapeutic approach remains unclear.
OBJECTIVE: To investigate how resveratrol, a natural stilbene compound, influences balance disturbances in individuals with knee OA METHOD: In a randomized double blind clinical trial, 129 patients with OA were allocated to receive either placebo (n = 67) or resveratrol at a daily dose of 500 mg (n = 62) for 18 weeks. Assessments included Oxford Knee Score (OKS), WOMAC index, knee flexion range of motion (ROM), gait speed, handgrip strength, balance scores, and plasma concentrations of SIRT1 and C-reactive protein (CRP), recorded at baseline and again after 18 weeks.
RESULTS: Resveratrol significantly improved balance, gait speed, knee ROM, HGS, and reduced pain during walking and WOMAC scores (all p < 0.05), without affecting OKS or resting pain. Plasma SIRT1 increased, and CRP decreased in the resveratrol group. SIRT1 levels correlated strongly with balance scores post-treatment (r²=0.322, p < 0.0001), more than in placebo (r²=0.084, p = 0.017) or baseline values.
CONCLUSION: Resveratrol alleviated OA symptoms and postural imbalance, potentially through anti-inflammatory effects mediated by elevated plasma SIRT1.
OBJECTIVE: To investigate how resveratrol, a natural stilbene compound, influences balance disturbances in individuals with knee OA METHOD: In a randomized double blind clinical trial, 129 patients with OA were allocated to receive either placebo (n = 67) or resveratrol at a daily dose of 500 mg (n = 62) for 18 weeks. Assessments included Oxford Knee Score (OKS), WOMAC index, knee flexion range of motion (ROM), gait speed, handgrip strength, balance scores, and plasma concentrations of SIRT1 and C-reactive protein (CRP), recorded at baseline and again after 18 weeks.
RESULTS: Resveratrol significantly improved balance, gait speed, knee ROM, HGS, and reduced pain during walking and WOMAC scores (all p < 0.05), without affecting OKS or resting pain. Plasma SIRT1 increased, and CRP decreased in the resveratrol group. SIRT1 levels correlated strongly with balance scores post-treatment (r²=0.322, p < 0.0001), more than in placebo (r²=0.084, p = 0.017) or baseline values.
CONCLUSION: Resveratrol alleviated OA symptoms and postural imbalance, potentially through anti-inflammatory effects mediated by elevated plasma SIRT1.